Drug Profile
Insulin glargine biosimilar - HEC Pharm
Alternative Names: HEC-glargineLatest Information Update: 06 Jan 2023
Price :
$50
*
At a glance
- Originator HEC Pharm
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Diabetes mellitus
Most Recent Events
- 04 Jan 2023 Lannett announces intention to submit Biologics License Application (BLA), under the the 351(k) biosimilar pathway, to the US FDA for Diabetes mellitus in mid-year 2023
- 31 Aug 2022 Lannett completes a phase I trial in Diabetes mellitus (In volunteers) in South africa (NCT05248841)
- 01 Jun 2022 Lannett announces intention to launch insulin glargine biosimilar in first half of 2024